Role of Dexmedetomidine as Synergistic Agent

Phase 2/3 Not yet recruiting 166 enrolled Lady Reading Hospital, Pakistan

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this clinical trial is to contribute valuable insights into the role of Dexmedetomidine as a synergistic agent in prolonging subarachnoid block duration, with the overarching goal of enhancing perioperative care and surgical success rates.

Timeline

Start: 2024-11
Primary completion: 2025-07
Completion: 2025-09

Publications

Background Sharma A, Varghese N, Venkateswaran R. Effect of intrathecal dexmedetomidine versus intravenous dexmedetomidine on subarachnoid anesthesia with hyperbaric bupivacaine. J Anaesthesiol Clin Pharmacol. 2020 Jul-Sep;36(3):381-385. doi: 10.4103/joacp.JOACP_323_17. Epub 2020 Sep 14.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexmedetomidine	Other / unclassified	—	Intravenous
Background	Bupivacaine	Other / unclassified	2 ml	Intrathecal

Indications

No indication recorded.